Vertex Pharmaceuticals reported Q3 2026 revenue of $3.44 billion, slightly above the $3.41 billion analyst consensus, while adjusted EPS of $4.76 matched expectations. The company raised its full-year revenue guidance to $13.15–$13.25 billion from $13.10–$13.20 billion, although the new midpoint of $13.2 billion remained slightly below Wall Street estimates. Growth in newer products provided additional momentum: CASGEVY revenue reached $99 million, up 30% sequentially and nearly sixfold year over year, while JOURNAVX generated $58 million, rising 18% quarter over quarter and nearly tripling from Q3 2025. Vertex also completed its approximately $9 billion net-of-cash acquisition of Crinetics Pharmaceuticals in September, expanding into rare endocrine diseases, and recorded $10 million in PALSONIFY revenue after the deal closed. $VRTX